New therapies for hepatitis C virus infection.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Clinical Infectious Diseases

• Publication date

  2009-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1086/595848PMID 19123867
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C.

  2009cited by this paper
• 995 INTERIM RESULTS FROM HCV SPRINT-1: RVR/EVR FROM PHASE 2 STUDY OF BOCEPREVIR PLUS PEGINTRONTM (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE-1 CHC

  2008cited by this paper
• Robust antiviral activity of R1626, a novel nucleoside analog: A randomized, placebo‐controlled study in patients with chronic hepatitis C

  2008cited by this paper
• 3 COLCHICINE VERSUS PEG-INTERFERON ALFA 2B LONG TERM THERAPY: RESULTS OF THE 4 YEAR COPILOT TRIAL

  2008cited by this paper
• The emerging field of HCV drug resistance.

  2008cited by this paper
• 58 TREATMENT OF CHRONIC HEPATITIS C WITH TELAPREVIR (TVR) IN COMBINATION WITH PEGINTERFERON-ALFA-2A WITH OR WITHOUT RIBAVIRIN: FURTHER INTERIM ANALYSIS RESULTS OF THE PROVE2 STUDY

  2008cited by this paper
• 4 PROVE1: RESULTS FROM A PHASE 2 STUDY OF TELAPREVIR WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH HEPATITIS C

  2008cited by this paper
• 851 ANTIVIRAL POTENCY OF R1479, ACTIVE COMPOUND DERIVED IN VIVO FROM PRODRUG R1626, DEMONSTRATED ACROSS HCV GENOTYPES 1-6 IN NS5B RECOMBINANT ENZYMES AND HCV REPLICONS

  2008cited by this paper
• Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?

  2008cited by this paper
• Emerging drugs for hepatitis C

  2008cited by this paper
• R1626 plus peginterferon Alfa‐2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin

  2008cited by this paper
• 841 EFFICACY AND SAFETY OF 2 YEARS MAINTENANCE THERAPY WITH PEGINTERFERON ALPHA-2A IN CHRONIC HEPATITIS C: RESULTS OF A RANDOMIZED CONTROLLED TRIAL (FIBROSYS)

  2008cited by this paper
• Thrombocytopenia associated with chronic liver disease.

  2008cited by this paper
• 996 TREATMENT WEEK 12 RESULTS OF WEIGHT-BASED TARIBAVIRIN VERSUS WEIGHT-BASED RIBAVIRIN, BOTH WITH PEGINTERFERON ALFA-2B, IN NAIVE CHRONIC HEPATITIS C, GENOTYPE 1 PATIENTS

  2008cited by this paper
• High relapse rate seen at week 72 for patients treated with R1626 combination therapy

  2008cited by this paper
• [791] HCV ANTIVIRAL ACTIVITY AND RESISTANCE ANALYSIS IN CHRONICALLY INFECTED CHIMPANZEES TREATED WITH NS3/4A PROTEASE AND NS5B POLYMERASE INHIBITORS

  2007cited by this paper
• Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study.

  2007cited by this paper
• Viral hepatitis in HIV infection.

  2007cited by this paper
• Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus.

  2007cited by this paper
• Viral hepatitis in HIV infection.

  2007cited by this paper
• Antiviral activity of telaprevir (VX‐950) and peginterferon alfa‐2a in patients with hepatitis C

  2007cited by this paper
• Future Treatment of Chronic Hepatitis C

  2007cited by this paper
• The hepatitis C virus life cycle as a target for new antiviral therapies.

  2007cited by this paper
• Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.

  2007cited by this paper
• Telaprevir and pegylated interferon–alpha‐2a inhibit wild‐type and resistant genotype 1 hepatitis C virus replication in patients

  2007cited by this paper
• In Vitro Resistance Study of AG-021541, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase

  2007cited by this paper
• Viral hepatitis and liver transplantation.

  2006cited by this paper
• VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells

  2006cited by this paper
• SCH 503034, a Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease, Suppresses Polyprotein Maturation and Enhances the Antiviral Activity of Alpha Interferon in Replicon Cells

  2006cited by this paper
• The culture of designing hepato-biliary randomised trials.

  2006cited by this paper
• Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease.

  2006cited by this paper
• In vitro selected Con1 subgenomic replicons resistant to 2'-C-methyl-cytidine or to R1479 show lack of cross resistance.

  2006cited by this paper
• The Novel Nucleoside Analog R1479 (4′-Azidocytidine) Is a Potent Inhibitor of NS5B-dependent RNA Synthesis and Hepatitis C Virus Replication in Cell Culture*

  2006cited by this paper
• Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease

  2006cited by this paper
• Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.

  2006influential reference
• Nonstructural protein 5B of hepatitis C virus.

  2006cited by this paper
• 78 The HCV NS3 protease inhibitor SCH 503034 in combination with PEG-IFNα-2b in the treatment of HCV-1 PEG-IFNα-2b non-responders: Antiviral activity and HCV variant analysis

  2006cited by this paper
• Antiviral efficacy of NS3‐serine protease inhibitor BILN‐2061 in patients with chronic genotype 2 and 3 hepatitis C

  2005cited by this paper
• Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

  2005cited by this paper
• Mechanisms of action of ribavirin against distinct viruses

  2005cited by this paper
• Binding Site Characterization and Resistance to a Class of Non-nucleoside Inhibitors of the Hepatitis C Virus NS5B Polymerase*

  2005cited by this paper
• Replicon Cell Culture System as a Valuable Tool in Antiviral Drug Discovery against Hepatitis C Virus

  2005cited by this paper
• Replication Fitness and NS5B Drug Sensitivity of Diverse Hepatitis C Virus Isolates Characterized by Using a Transient Replication Assay

  2005cited by this paper
• Mutations Conferring Resistance to a Potent Hepatitis C Virus Serine Protease Inhibitor In Vitro

  2004cited by this paper
• In Vitro Resistance Studies of Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061

  2004cited by this paper
• Treatment of Chronic Hepatitis C Infection with Peginterferons Plus Ribavirin

  2004cited by this paper
• Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.

  2004cited by this paper
• Inhibition of Hepatitis C Virus RNA Replication by 2′-Modified Nucleoside Analogs*

  2003cited by this paper
• An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

  2003cited by this paper
• Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon

  2003cited by this paper
• Mechanismof Action and Antiviral Activity of Benzimidazole-Based AllostericInhibitors of the Hepatitis C Virus RNA-Dependent RNAPolymerase

  2003cited by this paper
• Characterization of Resistance to Non-obligate Chain-terminating Ribonucleoside Analogs That Inhibit Hepatitis C Virus Replication in Vitro*

  2003cited by this paper
• Structural Analysis of the Hepatitis C Virus RNA Polymerase in Complex with Ribonucleotides

  2002cited by this paper
• Nucleotide triphosphatase/helicase of hepatitis C virus as a target for antiviral therapy.

  2002cited by this paper
• New therapeutic strategies for hepatitis C

  2002cited by this paper
• Hepatitis C Virus RNA-dependent RNA Polymerase (NS5B) as a Mediator of the Antiviral Activity of Ribavirin*

  2001cited by this paper
• Hepatitis C Virus-Encoded Enzymatic Activities and Conserved RNA Elements in the 3′ Nontranslated Region Are Essential for Virus Replication In Vivo

  2000cited by this paper
• Viral hepatitis and liver transplantation

  1999cited by this paper
• Replication of Subgenomic Hepatitis C Virus Rnas in a Hepatoma Cell Line

  1999cited by this paper
• Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site

  1999cited by this paper
• Characterization and mutational analysis of the helicase and NTPase activities of hepatitis C virus full-length NS3 protein.

  1999cited by this paper
• Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line.

  1999cited by this paper

• Plant-based production of virus-like particles from hepatitis C virus

  2026cites this paper
• Hepatitis C transmission and progression among people who have injected drugs in Singapore: Modelling treatment for eradication

  2025cites this paper
• Evaluation of Risk Determinants and Molecular Characterisation for Non-Primate Hepacivirus Infection in Turkish Horses

  2025cites this paper
• Prevalence of hepatitis C virus infection in Qatar’s resident population based on a national screening campaign

  2025cites this paper
• Prevalence of hepatitis B and C viruses among migrant workers in Qatar

  2024cites this paper
• Novel Pyrazino[1,2-a]indole-1,3(2H,4H)-dione Derivatives Targeting the Replication of Flaviviridae Viruses: Structural and Mechanistic Insights

  2024cites this paper
• Advancing Toward a Hepatitis C-Free World: Emerging Therapies, Persistent Challenges, and Future Prospects

  2024cites this paper
• Novel Lipophilic Hydroxamates Based on Spirocarbocyclic Hydantoin Scaffolds with Potent Antiviral and Trypanocidal Activity

  2023cites this paper
• Impact of Direct-Acting Antiviral Therapy on Liver Fibrosis Regression among People with Chronic HCV Infection: Results from a Real-Life Cohort in Patients Who Achieved Sustained Virological Response

  2023cites this paper
• Novel 6-Aminoquinazolinone Derivatives as Potential Cross GT1-4 HCV NS5B Inhibitors

  2022cites this paper
• Prevalence of Hepatitis C Virus among the Healthy Blood Donors in the Department of Transfusion Medicine of a Teaching Hospital

  2022cites this paper
• Hepatitis C: diagnosis, treatment and harm‐reduction strategies

  2022cites this paper
• Effect of directly acting anti-viral agents on immunological imprints in chronic HCV-4a patients: interleukin-10 and vascular endothelial growth factor genes expression level

  2021cites this paper
• Self-reported hepatitis C(HCV) testing among people living with human immunodeficiency virus (PLWH)

  2021cites this paper
• In Vitro Antiviral Activity of Tyrosinase from Mushroom Agaricus bisporus against Hepatitis C Virus

  2021influential citation
• COVID-19: Characteristics and Therapeutics

  2021cites this paper
• Hepatitis C Virus E1 Protein Enhances Macrophage iNOS Expression In Vitro

  2021cites this paper
• Reported Barriers to Hepatitis C Treatment among Pregnant and Early-Parenting Mothers Undergoing Substance Use Disorder Treatment in One U.S. State

  2021cites this paper
• Virtual Screening and Molecular Docking of FDA Approved Antiviral Drugs for the Identification of Potential Inhibitors of SARS-CoV-2 RNA-MTase Protein

  2021cites this paper
• Hepatitis C Virus (HCV) Prediction by Machine Learning Techniques

  2020cites this paper
• Long‐term safety and efficacy results in hepatitis C virus genotype 1‒infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ‐I and TOPAZ‐II trials

  2020cites this paper
• Algorithms for the Testing of Tissue Donors for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus

  2020cites this paper
• Tyrosinase from mushroom Agaricus bisporus as an inhibitor of the Hepatitis C virus

  2020cites this paper
• CHARACTERIZING THE ASSOCIATION BETWEEN POSITIVE HCV ANTIBODY AND PAIN AMONG PEOPLE WHO INJECT DRUGS

  2020cites this paper
• Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study

  2020cites this paper
• The importance of synthetic chemistry in the pharmaceutical industry

  2019cites this paper
• Characterising the association between positive hepatitis C virus antibody and pain among people who inject drugs.

  2019cites this paper
• COMPARISON OF ADHERENCE AND PREVALENCE OF DEPRESSION AMONG HEPATITIS C INFECTED CIRRHOTIC AND NON-CIRRHOTIC PATIENTS TREATED WITH PEGYLATED INTERFERON PLUS RIBAVIRIN VERSUS DIRECT-ACTING ANTIVIRALS

  2019cites this paper
• Significant Improvement in Diagnosis of Hepatitis C Virus Infection by a One-Step Strategy in a Central Laboratory: an Optimal Tool for Hepatitis C Elimination?

  2019cites this paper
• Mitochondria in the biology, pathogenesis, and treatment of hepatitis virus infections

  2019cites this paper
• Scaffold hybridization strategy towards potent hydroxamate-based inhibitors of Flaviviridae viruses and Trypanosoma species.

  2019cites this paper
• Characterization of functional determinants in the C-terminal part of hepatitis C virus E1 glycoprotein ectodomain

  2019cites this paper
• Symmetric Anti-HCV Agents: Synthesis, Antiviral Properties, and Conformational Aspects of Core Scaffolds

  2019cites this paper
• Hepatitis E Virus Infection and the Treatment

  2019cites this paper
• Evaluating the centralized purchasing policy for the treatment of hepatitis C: The Colombian CASE

  2019cites this paper
• Use of Modified Clostridium perfringens Enterotoxin Fragments for Claudin Targeting in Liver and Skin Cells

  2019cites this paper
• Dynamics and management of oral anticoagulant treatment in chronic hepatitis C patients undergoing therapy with direct antiviral agents

  2019cites this paper
• Prevalence of hepatitis B, C and D among patients on highly active antiretroviral drug therapy (HAART) in Calabar metropolis, Nigeria

  2018cites this paper
• Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C

  2018cites this paper
• A fatal case of bipolar disorder and comorbid hepatitis C

  2018cites this paper
• AIDS Clinical Research in Spain—Large HIV Population, Geniality of Doctors, and Missing Opportunities

  2018cites this paper
• Hepatitis C virus core protein-induced miR-93-5p up-regulation inhibits interferon signaling pathway by targeting IFNAR1

  2018cites this paper
• Expanding the chemical space of anti‐HCV NS5A inhibitors by stereochemical exchange and peptidomimetic approaches

  2018cites this paper
• Flavonoids from Pterogyne nitens Inhibit Hepatitis C Virus Entry

  2017cites this paper
• Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C

  2017influential citation
• Awareness Survey of Prejudice and Discrimination in Hepatitis B and C Virus- Infected Individuals

  2017cites this paper
• Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A

  2017cites this paper
• Preface The liver consists of different cell types including hepatocytes , endothelial cells , stellate cells

  2017cites this paper
• Novel nucleoside analogues targeting HCV replication through an NS5A‐dependent inhibition mechanism

  2017cites this paper
• Clinical outcomes of direct-acting antiviral therapy in patients with compensated hepatitis C virus-related cirrhosis

  2017cites this paper
• Direct antiviral agents (DAAs) ‐ A new age in the treatment of hepatitis C virus infection

  2017cites this paper
• Awareness Survey of Prejudice and Discrimination

  2017cites this paper
• New combination antiviral for the treatment of hepatitis C.

  2016cites this paper
• Design and synthesis of pyridine-pyrazole-sulfonate derivatives as potential anti-HBV agents

  2016cites this paper
• Identification of Bioactive Compound from Microalga BTM 11 as Hepatitis C Virus RNA Helicase Inhibitor

  2016cites this paper
• A Review of Hepatitis C in the General Population in Pakistan

  2016cites this paper
• Novel indole–flutimide heterocycles with activity against influenza PA endonuclease and hepatitis C virus

  2016cites this paper
• Optimisation of triple therapy for patients with chronic hepatitis C: a systematic review

  2016cites this paper
• Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies

  2016cites this paper
• Formación médica continuada: Infección por el VIH en el adulto Infección por virus de la inmunodeficiencia humana y hepatitis víricas

  2016cites this paper
• Molecular dynamics study on drug resistance mechanism of HCV NS3/4A protease inhibitor: BI201335

  2015cites this paper
• Asunaprevir for hepatitis C: a safety evaluation

  2015cites this paper
• A new role for PGA1 in inhibiting hepatitis C virus-IRES-mediated translation by targeting viral translation factors.

  2015cites this paper
• Overcoming stability challenges in the quantification of tissue nucleotides: determination of 2'-C-methylguanosine triphosphate concentration in mouse liver.

  2015cites this paper
• Optimisation of a potent series of HCV helicase drug candidates

  2015cites this paper
• Insights into antiviral innate immunity revealed by studying hepatitis C virus.

  2015cites this paper
• Exploring resistance mechanisms of HCV NS3/4A protease mutations to MK5172: insight from molecular dynamics simulations and free energy calculations.

  2015cites this paper
• Diterbitkan Oleh: Perhimpunan Biologi Indonesia

  2015cites this paper
• Hepatitis C virus and antiviral innate immunity: who wins at tug-of-war?

  2015cites this paper
• Emergence of resistant variants detected by ultra‐deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1

  2015cites this paper
• Comprehensive Review in Current Developments of Benzimidazole‐Based Medicinal Chemistry

  2015cites this paper
• Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?

  2015cites this paper
• IL-26 is overexpressed in chronically HCV-infected patients and enhances TRAIL-mediated cytotoxicity and interferon production by human NK cells

  2014cites this paper
• Impact of Hepatitis C Treatment Initiation on Adherence to Concomitant Medications

  2014cites this paper
• Pattern and associated factors of anti-hepatitis C virus treatment-induced adverse reactions

  2014cites this paper
• Replication priority of hepatitis C virus genotype 2a in a Chinese cohort

  2014cites this paper
• Disruption of Bcl-2 and Bcl-xL by viral proteins as a possible cause of cancer

  2014cites this paper
• Activation and evasion of antiviral innate immunity by hepatitis C virus.

  2014cites this paper
• Pushing to a cure by harnessing innate immunity against hepatitis C virus.

  2014cites this paper
• A Novel Human Radixin Peptide Inhibits Hepatitis C Virus Infection at the Level of Cell Entry

  2014cites this paper
• Mathematical analysis of hepatitis C model for intravenous drug misusers: Impact of antiviral therapy, abstinence and relapse

  2014cites this paper
• Serum proteomics of hepatitis C virus infection reveals retinol-binding protein 4 as a novel regulator.

  2014cites this paper
• Report : Effect of Bee Stings on the Viral Clearance in Chronic Hepatitis-C Virus

  2014cites this paper
• CLINICAL AND SOCIAL ASPECTS OF PATIENTS WITH VIRAL CHRONIC HEPATITIS C IN BIHOR COUNTY Mirela Indrieş

  2014cites this paper
• Cost‐effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection

  2014cites this paper
• Occurrence of hepatitis 'B' and 'C' amongst patients on antiretroviral drug therapy (ART) in a treatment centre in Calabar, Nigeria

  2014cites this paper
• Naturally Occurring Mutations in the Nonstructural Region 5B of Hepatitis C Virus (HCV) from Treatment-Naïve Korean Patients Chronically Infected with HCV Genotype 1b

  2014cites this paper
• Understanding the drug resistance mechanism of hepatitis C virus NS5B to PF-00868554 due to mutations of the 423 site: a computational study.

  2014cites this paper
• N-Substituted Benzyl Matrinic Acid Derivatives Inhibit Hepatitis C Virus (HCV) Replication through Down-Regulating Host Heat-Stress Cognate 70 (Hsc70) Expression

  2013cites this paper
• No Correlation between PNPLA3 rs738409 Genotype and Fatty Liver and Hepatic Cirrhosis in Japanese Patients with HCV

  2013cites this paper
• Sustained and rapid virological responses in hepatitis C clinical trials

  2013cites this paper
• The kinase inhibitor Sorafenib impairs the antiviral effect of interferon α on hepatitis C virus replication.

  2013cites this paper
• Virtual screening of imidazole analogs as potential hepatitis C virus NS5B polymerase inhibitors

  2013cites this paper
• What about us? Recent advances in the treatment of chronic hepatitis C threaten to leave some parts of the world behind

  2013cites this paper
• Restoration of type I interferon expression by heme and related tetrapyrroles through inhibition of NS3/4A protease.

  2013cites this paper
• Control of hepatitis C virus genome replication by viral factors and mediators of host intrinsic immunity

  2013cites this paper
• KEEPING WATCH: MONITORING INFECTIOUS DISEASE RISKS TO THE ORANGE AFRICA CUP OF NATIONS, 2013

  2013cites this paper
• Molecular Design, Synthesis and Cell Based HCV Replicon Assay of Novel Benzoxazole Derivatives

  2013cites this paper
• In Vivo Interferon-Alpha/Ribavirin Treatment Modulates Vγ9Vδ2 T-Cell Function During Chronic HCV Infection

  2013cites this paper
• Regulation of hepatic innate immunity by hepatitis C virus

  2013influential citation